MedTrace Logo

Long-term Follow-up of Study Participant Treated With Lentiviral-Based Genetically Modified Autologous Cell Product ,AGT103-T

NCT05529342 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2022-12-02

No results posted yet for this study

Summary

Long-term follow-up of study subjects who received AGT103-T product in HIV study. The AGT103-T is genetically modified cells that resist infection with HIV causing a depletion of HIV in HIV-infected study participants.

Conditions

Interventions

BIOLOGICAL

Gene modified therapy

No investigational cell product will be administered

Sponsors & Collaborators

  • American Gene Technologies International Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-29
Primary Completion
2038-05-23
Completion
2038-09-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05529342 on ClinicalTrials.gov